7月 2026
- 首頁
- Credo Diagnostics Biomedical
7月 2026Credo Diagnostics Biomed...的市場佔有率分析
Privacy Policy This Privacy Policy (“Policy”) describes how Credo Diagnostics Biomedical Pte. Ltd. including its subsidiaries and affiliates, (together referred to as “Credo Diagnostics”) handles the personal information that you provide to on websites controlled by Credo Diagnostics which link to this Policy (together referred to as “Website(s)”). Your use of Website(s) is subject to […]
Credo Diagnostics Biomedical(包含公司地區)
查看更多網站流量與參與度資訊- credodxbiomed.com
Credo Diagnostics Biomedical截至 7月 2026 的總收入為 2M - 5M
Credo Diagnostics Biomedical 熱門網域產生的總收入
Credo Diagnostics Biomedical 熱門網域 3 年內的總收入
Credo Diagnostics Biomedical 熱門網域的總收入
Credo Diagnostics Biomedical的熱門網域總造訪量
了解Credo Diagnostics Biomedical市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
Credo Diagnostics Biomedical的熱門網域平均造訪時長
分析Credo Diagnostics Biomedical參與度指標。
過去 3 個月平均造訪時長
子公司細目
Credo Diagnostics Biomedical的熱門網域平均頁面瀏覽量
了解Credo Diagnostics Biomedical如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自Credo Diagnostics Biomedical
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Credo Diagnostics Biomedical Pte. Ltd launched VitaPCR TM on Jan 1st '19.Founded in 2011, Credo Diagnostics launched the VitaPCR TM in 2019, a revolutionary molecular biology platform capable of detecting infectious pathogens (including the SARS-CoV-2 responsible for Covid-19, influenza and RSV viruses) by Polymerase Chain Reaction (PCR) methodology in only 20 minutes.
1月 13, 2023閱讀更多
查看所有Credo Diagnostics Biomedical信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
